27% growth in prescriptions dispensed over prior quarter; 147% growth over comparable quarter in 2022. 5 consecutive quarters of double-digit growth. Click here to learn more ›

Palatin Technologies to Present at the 12th Annual BIO Investor Forum

CRANBURY, N.J., Oct. 4, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 12th Annual BIO Investor Forum on Tuesday, October 8, 2013 at 3:30 p.m. Pacific Time.  Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum will take place October 8-9 at The Palace Hotel in San Francisco, CA. 

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin’s corporate and development programs. 

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at http://www.palatin.com

SOURCE Palatin Technologies, Inc.

Scroll to Top